Oribiotech deal validates AdAlta manufacturing strategy

Key points

• Oribiotech signs a 10-year, US$120 million partnership to integrate IRO® platform
• Validates AdAlta's chosen manufacturing automation strategy
• Future AdAlta products will be made on a platform already in commercial use

Full summary

AdAlta Limited (ASX:1AD) has announced that its cell therapy manufacturing automation partner, Oribiotech Ltd, has signed a 10-year partnership worth up to US$120 million with an undisclosed commercial stage partner to integrate its IRO® platform into the manufacture of an already approved and commercialized cell therapy. This partnership validates AdAlta's chosen manufacturing automation platform, IRO®, which is designed to deliver 10 to 50 times more output from the same footprint and 30-50% lower manufacturing costs, with more consistent product quality. The partnership signifies that future AdAlta products developed on IRO® will be made on a platform industry has already validated and put into commercial use.